Alzheimer's Drug Market Risk Analysis Brief.

Alzheimer's disease (AD), commonly known as Alzheimer's disease, is a degenerative disease of the nervous system that develops in a hidden way, characterized clinically by memory impairment, aphdclaves, loss of use, disrecognation, impairment of visual spatial skills, dysfunction of execution, and changes in personality and behavior.
drugs are the main treatment methods at present, with controlled treatment accompanied by psychotic symptoms of drugs (anti-anxiety, antipsychotic drugs) and noobials or drugs to improve cognitive function (drugs that act on neurotransmitter or brain metabolism).
The World Health Organization (WHO) noted in 2017 that there are about 50 million AD patients worldwide, nearly 60 percent of whom live in low- and middle-income countries, and that the total number of patients worldwide is expected to reach 82 million by 2030 and 152 million by 2050.
China has the largest elderly population in the world, with 249.49 million people aged 60 and over at the end of 2018, or 17.9 percent of the total population, according to the latest figures from the National Bureau of Statistics.
estimates that there are more than 10 million AD patients in China, the largest in the world, and the number of AD patients is expected to exceed 22 million by 2040, with great market potential.
Neurological and psychotic diseases are currently the most popular clinical research areas in the world except in the field of oncology, Andersen pharmaceutical companies such as Shanghai Green Valley Pharmaceuticals, Green Leaf Pharmaceuticals, Dongsian Pharmaceuticals, etc. have laid out AD's new drug research and development, according to the State Drug Administration data, up to now a total of 77 clinical trials of AD drugs.
ganlut sodium was approved in China on November 2, 2019 for mild to moderate Alzheimer's disease to improve cognitive function in patients.
There are not many drugs for AD treatment at present (Figure 1), a study based on 2017 Shanghai hospital prescription data shows that the amount of AD drugs treated is mostly chemicals, the amount of which is as high as 94.8%, followed by Chinese medicine, the amount of about 4.7%, the amount of biological products drugs accounted for only 0.5%.
of these, the largest proportion was 42.88 per cent, the second was donai pythonzy about 25.76 per cent, the third was Olasitan about 14.31 per cent and the fourth was Kabalatin about 5.11 per cent.
Chart 1. Currently approved major AD drug name drug type adaptive drug market time manufacturer Taclin (de-marketed) cholinesterase inhibitor mild moderate AD1993.09 (FDA) First Horizon Donaizi cholinesterase inhibitor all stages AD1996.11 (FDA) Japanese ingredient Kabaratin cholinesterase inhibitor all stages AD1998.05 (FDA) Huagarantamine cholinesterase inhibitor mild-moderate AD2001.02 (FDA) U.S. Johnson ampere excitable amino acid inhibitor medium-heavy AD2003.01 (FDA) Danish Ling North American King Kong and Donai pyridoacide excitable amino acid inhibitor s/cholinesterase inhibitor medium-heavy AD2014.12 (FDA) Actavis/ Adamas Ganlut sodium low molecular acid oligosaccharide compound mild-moderate AD2019.11 (NMPA) Shanghai Green Valley Source: Public information SGRCR finishing industry risk 1. New drug research and development difficulties Currently the FDA has approved only 5 therapeutic AD drugs on the market, no new drugs in recent years The drug was approved, and globally, the research and development of new AD drugs remains critical, with PhRMA reporting that between 1998 and 2017, 146 AD drugs worldwide failed clinically, with a clinical failure rate of 97.3 percent.
2. Changes in drug design Cancer drugs are now beginning to move toward multi-target design and gene therapy that can be more effective in controlling disease.
the failure of AD's single-target design in the past is also a factor, and because of the complex pathogenesis of AD, multi-target design and gene therapy may become mainstream of future drugs.
3. The fierce competition in the generic drug market once the original research drug once the patent period, is bound to face a number of products of competition, such as Donai pyridodge into the market more enterprises, has been listed approved enterprises including Huahai Pharmaceuticals, Howson Pharmaceuticals, Ark Pharmaceuticals, San Jiyi Pharmaceuticals, Li Biopharmaceuticals, Shien Pharmaceuticals, Yangzijiang Pharmaceuticals, Haixin Pharmaceuticals, Haizheng Pharmaceuticals, Xinda Pharmaceuticals, Luoxin Pharmaceuticals, Jinzhi Pharmaceuticals, Furen Pharmaceuticals, Fangming Pharmaceuticals and Shenghe Pharmaceuticals are also great challenges to the ability of enterprise marketing.
.